Table 1 Reported cases of torpedo maculopathy with greater than 1 year of follow-up
From: Long-term follow-up of torpedo maculopathy: a case series and mini-review
AUTHORa | YEAR | SEX | AGEb | F/U | FINDINGS |
|---|---|---|---|---|---|
Current study | Â | F | 25 | 10 Y | No change |
Current study | Â | F | 22 | 10 Y | Retinal degeneration |
Sanabria-1 [11] | 2008 | F | 12 | 5 Y | Retinal thinning |
Sanabria-2 [11] | 2008 | F | 13 | 5 Y | Enlargement |
Hansen [33] | 2016 | M | 12 | 5 Y | No change |
Rohl [8] | 2016 | M | 10 | 5 Y | Enlargement and ovalization |
Giannakaki-1 [19] | 2019 | F | 8 | 5 Y | Stable VA |
Pian-1 [34] | 2003 | M | 59 | 4 Y | No change |
Golchet-1 [35] | 2010 | F | 33 | 4 Y | No change |
Dutra [36] | 2013 | F | 5 | 4 Y | No change |
Pian-2 [34] | 2003 | M | 63 | 3 Y | No change |
Schuerch-1 [37] | 2015 | F | 3 | 3 Y | No change |
de Manuel-1 [38] | 2016 | M | 4 | 3 Y | No change |
Suarez [39] | 2017 | F | 4 | 3 Y | No change |
Ehrenberg-2 [40] | 2023 | F | 2 | 3 Y | No change |
Ehrenberg-5 [40] | 2023 | F | 7 | 3 Y | No change |
Ehrenberg-6 [40] | 2023 | M | 4 | 3 Y | No change |
Ehrenberg-7 [40] | 2023 | M | 4 | 3 Y | No change |
Ghezzaz [22] | 2023 | F | 74 | 2.5 Y | CNV Stable |
Pian-3 [34] | 2003 | M | 63 | 2 Y | No change |
Giannakaki-2 [19] | 2019 | F | 13 | 2 Y | Stable VA |
Ehrenberg-1 [40] | 2023 | F | 5 | 2 Y | No change |
Ehrenberg-10 [40] | 2023 | M | 3 | 2 Y | No change |
Ding [41] | 2019 | F | 30 | 15 MO | No change |